Skip to main content
SpringerLink
Log in

Production and characterization of a Tie2 agonist monoclonal antibody

  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

The Tie2 receptor and its known ligands, the angiopoietins, play a critical role in endothelial cell differentiation during the process of angiogenesis. Recent experimental observations indicate that the agonistic ligand, angiopoietin-1, can stimulate endothelial cell sprouting and act as a chemo-attractant in vitro and induce increased and enhanced angiogenesis both alone and in conjunction with vascular endothelial growth factor (VEGF) in vivo. Here, we present a monoclonal antibody (MAb), which binds to the extracellular portion of the Tie2 receptor and elicits similar agonist effects. Upon MAb binding to the native Tie2 receptor of cultured human umblical vein endothelial cells (HUVEC), there is a rapid increase in receptor autophosphorylation with a concomitant enhancement in the recruitment and association of the signalling intermediates Grb2 and SH-PTP2. The antibody further demonstrates functional activity in vascular tissues. In vitro, the antibody promotes the survival of cultured HUVEC and elicits a dose dependent outgrowth and branching of microvessels from cultured explants of rat aorta. When administered in vivo, the antibody enhances the vascularization of subcutaneous Matrigel implants in mice. Together these data suggest that the antibody is capable of acting as a surrogate ligand for Tie2 and further confirms the role of Tie2 in the differentiation of endothelial cells during angiogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671.

    Article  PubMed  CAS  Google Scholar 

  2. Hanahan D. Signalling vascular morphogenesis and maintenance. Science 1997; 277: 48.

    Article  PubMed  CAS  Google Scholar 

  3. Jones PF. Tied up (or down?) with angiopoietins. Angiogenesis 1997; 1: 38.

    Article  PubMed  CAS  Google Scholar 

  4. Davis S, Aldrich TH, Jones PF et al. Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-Trap expression cloning. Cell 1996; 87: 1161.

    Article  PubMed  CAS  Google Scholar 

  5. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55.

    Article  PubMed  CAS  Google Scholar 

  6. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70.

    Article  PubMed  CAS  Google Scholar 

  7. Suri C, Jones PF, Patan S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171.

    Article  PubMed  CAS  Google Scholar 

  8. Asahara T, Chen D, Tomono T et al. Tie2 receptor ligands, Angiopoietin-1 and Angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83: 233.

    PubMed  CAS  Google Scholar 

  9. Suri C, McClain J, Thurston G et al. Increased vascularization in mice overexpressing Angiopoietin-1. Science 1998; 282: 468.

    Article  PubMed  CAS  Google Scholar 

  10. Koblizek TI, Weiss C, Yancopoulos GD et al. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 1998; 8: 529.

    Article  PubMed  CAS  Google Scholar 

  11. Witzenbichler B, Maisonpierre PC, Jones P et al. Chemotactic properties of Angiopoietin-1 and-2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998; 273: 18514.

    Article  PubMed  CAS  Google Scholar 

  12. Takakura N, Huang X, Naruse T et al. Immunity 1998; 9: 677.

    Article  PubMed  CAS  Google Scholar 

  13. Huang L, Turck CW, Rao P, Peters KG. GRB2 and SH-PTP2: potentially important endothelial signalling molecules downstream of the TEK/TIE2 receptor tyrosine kinase. Oncogene 1995; 11:2097.

    PubMed  CAS  Google Scholar 

  14. Kontos CD, Stauffer TP, Yang W et al. Tyrosine 1101 of Tie2 Is the major activation site of association of p85 and Is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol 1998; 18: 4131.

    PubMed  CAS  Google Scholar 

  15. Jones N, Dumont DJ. The TEK/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 1998; 17: 1097.

    Article  PubMed  CAS  Google Scholar 

  16. Clary DO, Weskamp G, Austin LR, Reichardt LF. TrkA Crosslinking mimics neuronal responses to nerve growth factor. Mol Biol Cell 1994; 5: 549.

    PubMed  CAS  Google Scholar 

  17. Schneider H, Chaovapong W, Matthews DJ et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 1997; 89: 473.

    PubMed  CAS  Google Scholar 

  18. Zola H (ed). Monoclonal Antibodies. London, UK, CRC Press Inc., 1987.

    Google Scholar 

  19. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press 1988.

    Google Scholar 

  20. Nicosia RF. The rat aorta model of angiogenesis and its application. In Mironov V, Little C, Sage H (eds): Microvascular Morphogenesis in Vivo, in Vitro and in Mente. Boston: Birkhauser 1998; 111.

    Google Scholar 

  21. Passaniti A, Taylor RM, Pili R et al. A Simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519.

    PubMed  CAS  Google Scholar 

  22. Lupia E, Montrucchio G, Battaglia E et al. Role of tumor necrosis factor-α and platelet activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996; 26: 1690.

    PubMed  CAS  Google Scholar 

  23. Biancone L, DeMartino A, Orlandi V et al. Development of inflammatory angiogenesis by local stimulation of fas in vivo. J Exp Med 1997; 186: 147.

    Article  PubMed  CAS  Google Scholar 

  24. Dumont DJ, Fong GH, Puri MC et al. Vascularizatio of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dynamics 1995; 203: 80.

    CAS  Google Scholar 

  25. Peters KG, Coogan A, Berry D et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumor angiogenesis. Br J Cancer 1998; 77: 51.

    PubMed  CAS  Google Scholar 

  26. Stratmann A, Risau W, Plate KH. Cell type-specific expression of Angiopoietin-1 and Angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459.

    PubMed  CAS  Google Scholar 

  27. Lin P, Buxton JA, Acheson A et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie-2. PNAS 1998; 95: 8829.

    Article  PubMed  CAS  Google Scholar 

  28. Lin P, Polverini P, Dewhirst M et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072.

    Article  PubMed  CAS  Google Scholar 

  29. Valenzuela DM, Griffiths JA, Rojas J et al. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. PNAS 1999; 96: 1904.

    Article  PubMed  CAS  Google Scholar 

  30. Wong AL, Haroon ZA, Werner S et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997; 81: 567.

    PubMed  CAS  Google Scholar 

  31. Koblizek TI, Runting AS, Stacker SA et al. Tie2 receptor expression and phosphorylation in cultured cells and mouse tissues. Eur J Biochem 1997; 244: 774.

    Article  PubMed  CAS  Google Scholar 

  32. Korpelainen EI, Karkkainen M, Gunji Y et al. Endothelial receptor tyrosine kinases activate the STAT signalling pathway: Mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999; 18: 1.

    Article  PubMed  CAS  Google Scholar 

  33. Lauren J, Gunji Y, Alitalo K. Is Angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol 1998; 153: 1333.

    PubMed  CAS  Google Scholar 

  34. Papapetropoulos A, Garcia-Cardena G, Dengler TJ et al. Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Oncology Research King of Prussia, SmithKline Beecham R & D, Pennsylvania, USA

    Michael J. Hansbury & James D. Winkler

  2. Department of Pathology and Lab Services, VA Puget Sound Health Care System, Seattle, Washington, USA

    Roberto F. Nicosia & Wen-Hui Zhu

  3. Antibody Technologies, New Fronteirs, UK

    Steven J. Holmes

Authors
  1. Michael J. Hansbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto F. Nicosia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen-Hui Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven J. Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James D. Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansbury, M.J., Nicosia, R.F., Zhu, WH. et al. Production and characterization of a Tie2 agonist monoclonal antibody. Angiogenesis 4, 29–36 (2001). https://doi.org/10.1023/A:1016678828930

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016678828930

Search

Navigation